CStone's Pratinib Capsules Announces Efficacy and Safety Data in the Treatment of NSCLC Chinese Patients

On September 9, CStone Pharmaceuticals announced that at the 2021 World Lung Cancer Conference (2021 IASLC WCLC) organized by the International Association for the Study of Lung Cancer, the company announced the selective RET inhibitor Pugeta® (Platin) in the form of an oral report.

The ARROW study (ClinicalTrials.

Effectiveness: Regardless of whether it has been treated in the past, Pugeta® has achieved rapid and long-lasting clinical activity in Chinese patients with RET fusion-positive advanced NSCLC

Patients who have previously received platinum-based chemotherapy (n=33.

The confirmed objective response rate (ORR) was 66.

Among 22 patients with confirmed remission, the median time to first remission was 1.

Patients who have not received systemic treatment (n=30.

The confirmed ORR was 80%, including 2 cases of complete remission and 22 cases of partial remission, and the DCR was 86.

Among 24 patients with confirmed remission, the median time to first remission was 1.

Safety: Pugeta® is well tolerated and safety is controllable

Pugeta® is well tolerated, and is overall safe and controllable in Chinese patients, and no new safety signals have been found

Note: The original text has been deleted